NCT07526961 2026-04-14
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Bristol-Myers Squibb
Completed
Clinical Trials
11 trialsNCT07394062 2026-02-06
ALCG-01
Gazi University
Recruiting
NCT06487156 2026-01-27
FINN
Bristol-Myers Squibb
Active not recruiting
NCT07215962 2025-10-14
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
Bristol-Myers Squibb
Active not recruiting
NCT07024862 2025-06-17
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
Bristol-Myers Squibb
Active not recruiting
NCT04291755 2024-04-05
Development and Analysis of a Stool Bank for Cancer Patients
Persephone Biosciences
Recruiting
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT04136470 2020-08-10
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Ardigen
Unknown
NCT04145232 2020-08-10
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
Ardigen
Unknown
NCT03695835 2020-07-22
NIRPA
Gary Onik MD
Completed